通过手术前风险替换 mitra 门后的长期存活率:对患者选择的影响
Matthew Kazaleh1, Catherine Wagner1, J'undra Pegues1
1Department of Cardiac Surgery, University of Michigan, Ann Arbor.
The Annals of thoracic surgery
|August 16, 2025
概括
胸腔外科医生协会 (STS) 预测性死亡风险 (PROM) 评分准确地预测了美特拉置换 (MVR) 后的5年生存期. 这个工具有助于更好地选择患者进行MVR手术.
科学领域:
- 心脏病学 心脏病学
- 心脏外科手术 心脏外科手术
- 医学统计 医学统计
背景情况:
- 中心替换 (MVR) 带有重大操作风险.
- 胸部外科医生协会 (STS) 预测死亡风险 (PROM) 计算器通常用于量化这些风险.
- 在孤立MVR后,STS PROM对长期结果的预测准确性需要进一步调查.
研究的目的:
- 评估STS PROM在接受隔离MVR的患者中的5年预测性能.
- 评估STS PROM分层风险组与实际长期死亡率之间的相关性.
- 为了确定与MVR后更糟糕的长期存活相关的患者特征.
主要方法:
- 分析了一组855名在高容量中心接受隔离MVR的患者.
- 根据STS PROM,患者被分为低 (<3%),中等 (3-6%) 和高/极端 (>6%) 风险组.
- 卡普兰-梅尔生存分析和考克斯回归建模用于评估死亡率并确定长期生存的预测因素.
主要成果:
- 五年生存率为90.8% (低风险),75.5% (中等风险) 和56.4% (高/极端风险),显示了各组的显著差异 (p<0.001).
- 在低风险和高风险/极端风险组中,三十天死亡率低于预期.
- 手术前透析,高血压和紧急手术状态被确定为更糟糕的长期生存预测因素.
结论:
- 在STS PROM中,即使在高容量中心,孤立的MVR后与5年死亡率存在相关性.
- 虽然预测模型在某些情况下可能会高估风险,但STS PROM仍然是风险分层的宝贵工具.
- 研究结果支持改进风险分层标准,以优化对MVR患者的选择.
更多相关视频
相关概念视频
Mitral Stenosis III: Medical Management
21
Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
21
Mitral Valve Prolapse II: Assessment and Management
39
IntroductionA range of clinical features characterizes Mitral Valve Prolapse (MVP), but it is important to note that many individuals with MVP are asymptomatic and may remain so throughout their lives. For those who do exhibit symptoms, the following are the key clinical features:Palpitations: This is a common symptom where individuals feel an irregular or rapid heartbeat. Palpitations in MVP are often due to arrhythmias such as premature ventricular contractions or supraventricular...
39
Mitral Stenosis IV: Nursing Management
46
A comprehensive nursing assessment is essential for patients with valvular heart disease, which involves any dysfunction of the heart valves that could impact blood flow and overall heart function.Subjective Data Collection:Chief Complaint and Present Illness: Start with the patient's primary concerns, focusing on the onset, duration, and progression of cardiac symptoms such as dyspnea, fatigue, chest pain, and palpitations.Past Medical History: Collect detailed information on any previous...
46
Mitral Valve Prolapse III: Nursing Management
36
The nursing management of Mitral Valve Prolapse, or MVP, centers around patient education, symptom monitoring, and lifestyle modifications.Patient Education on MVP Diagnosis and Heredity: Nurses should provide comprehensive education about MVP, a condition where the mitral valve does not close appropriately during heartbeats. This education often includes the condition's pathophysiology, symptoms, and potential complications, like arrhythmias or mitral regurgitation. Though not fully...
36
Mitral Stenosis I: Introduction
35
Mitral Valve Stenosis (MVS) is a heart condition where the mitral valve narrows, impeding blood circulation from the left atrium to the left ventricle. The etiology and pathophysiology of this condition are multifaceted, leading to a cascade of cardiovascular complications.Causes of Mitral Valve StenosisRheumatic Heart Disease: It is the main cause of mitral valve stenosis, particularly in developing nations. This condition arises from rheumatic fever, an inflammatory illness resulting from...
35
Mitral Regurgitation III: Medical Management
30
Mitral regurgitation (MR) is characterized by retrograde blood circulation from the left ventricle into the left atrium due to inadequate mitral valve closure. The severity of the condition, symptoms, and underlying cause determine treatment strategies.Monitoring and Pharmacological TreatmentPatients with mild to moderate MR typically do not need immediate intervention but regular monitoring to assess progression and guide treatment. Patients with mild MR should have an echocardiogram every 3-5...
30


